Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor

Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor

Source: 
Seeking Alpha
snippet: 

Merck KGaA (OTCPK:MKKGY) has brokered a licensing agreement with Nerviano Medical Sciences gaining access to NMS-293, a next-generation highly selective and brain-penetrant PARP1 inhibitor.